Egypt Edition 
MENA+ Edition 
UAE Edition 
Saudi Edition 
AI + Innovation (MENA) 
Infrastructure 
GSK only has eyes for Hikma
GlaxoSmithKline (GSK) has rejected separate takeover bids from Rameda and Acdima for its Egypt arm, focusing instead on talks with…
Rameda throws its hat in the ring for GSK’s Egypt business
Ladies and gentlemen, we have a good, old-fashioned bidding war: Rameda Pharma is the latest to show interest in GlaxoSmithKline's…
Earnings watch: Rameda, Edita, Sarwa, CI Capital, Amer Group
EARNINGS WATCH- Rameda profits soar in 3Q2020: Rameda Pharma reported 134% bottom line growth during 3Q2020, with net profits rising…
Earnings Watch: Orascom Development Egypt, Rameda, Fawry, B Investments, Raya, Beltone, ADIB, Oriental Weavers, GSK
EARNINGS WATCH- Rameda Pharma reported 54% bottom line growth in 2Q2020, with net profits rising to EGP 19.9 mn from…
What we’re tracking on 28 June 2020
Maybe we’re getting old, but we’re not used to all the noise in the post 9pm hours after months of…
What we’re tracking on 23 June 2020
Good morning, friends. Just two more days and we slide into the weekend. Have you made plans yet? Judging from…
Rameda acquires generic anti-inflammatory molecule
Rameda Pharma has acquired a generic anti-inflammatory molecule, according to a statement (pdf). The unnamed molecule, which relieves pain associated…
EGX sell-off continues as shares fall 7%
The selloff on the EGX continued yesterday, tripping circuit breakers yet again: The sell-off on the EGX continued at pace…
Something went wrong. Please refresh the page and/or try again.